This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: Q26.6 (portal vein–hepatic artery fistula) | Special Copayment Reduction: V150 |
| B. Synonyms | — |
| C. Adult onset | Likelihood of first onset in adulthood: moderate — congenital portal vein–hepatic artery fistula is rare; small fistulas may remain asymptomatic into adulthood and first present with portal hypertension, ascites, gastrointestinal bleeding, and so on. Large fistulas present early in childhood with heart failure, ascites, growth failure, and so on. The acquired form (trauma, complications after procedures) is more common in adults. |
| 1. History | History of the description of portal vein–hepatic artery fistula; distinction between congenital and acquired forms; treatment innovation following the introduction of percutaneous embolization. |
| 2. Causes | Congenital: abnormal development of the hepatic artery-portal venous system in the embryonic period. Acquired: trauma, liver biopsy, complications of liver procedures, HHT. |
| 3. Genetics | HHT (hereditary hemorrhagic telangiectasia): ENG, ACVRL1 (ALK1), SMAD4 variants; autosomal dominant inheritance. |
| 4. General epidemiology | Very rare disease; HHT-related hepatic arteriovenous fistula is the most common hereditary cause; the acquired form is more common than the congenital form. |
| 5. Pathophysiology | High-pressure arterial blood → inflow into the portal system → portal hypertension; or diversion of hepatic arterial flow → hepatic ischemia. |
| 6. Symptoms | Portal hypertension (ascites, variceal bleeding), heart failure (high-output), abdominal pain, abdominal vascular bruit, hepatomegaly. |
| 7. Signs | Abdominal vascular bruit, hepatomegaly, ascites, splenomegaly, varices, signs of heart failure. |
| 8. Screening | Screening ultrasound for hepatic vascular abnormalities in HHT patients; imaging evaluation when the cause of portal hypertension is unknown. |
| 9. Diagnosis | Abdominal Doppler ultrasound, CT/MR angiography, celiac arteriography (angiography), liver function tests. |
| 10. Treatment | Percutaneous vascular embolization (first choice); surgical ligation; liver transplantation (with severe HHT-related liver involvement). |
| 11. Prognosis | Good with early embolization of small fistulas; liver transplantation needed with extensive HHT-related liver involvement; prevention of complications of portal hypertension is key. |
| 12. Prevention | Regular liver ultrasound screening of HHT patients; careful surveillance for vascular complications after liver procedures. |
| 13. References | Garcia-Tsao G et al., Hepatology 2011; Lerut J et al., Liver Transpl 2006, and 8 other references |
Portal Vein–Hepatic Artery Fistula (ICD-10 Q26.6) is a rare vascular malformation consisting of an abnormal vascular connection (arteriovenous fistula) between the hepatic artery and the portal vein, through which high-pressure arterial blood flows directly into the portal system, causing portal hypertension and various systemic complications. The congenital form is very rare and is classified as Q26.6 in ICD-10. Acquired forms (trauma, liver biopsy, laparoscopic procedures, vascular invasion within liver cancer, aneurysm rupture, etc.) are more common.
Historical descriptions of this disease date back to the early 20th century. Congenital intrahepatic arteriovenous fistula was first described by Clarkson in 1917, followed by sporadic case reports. From the 1970s onward, the spread of selective celiac arteriography made diagnosis of intrahepatic vascular abnormalities possible. With the introduction of transcatheter arterial embolization (TAE) from the 1980s onward, noninvasive treatment without surgery became possible, greatly changing the treatment paradigm.
It was from the 1990s onward that Hereditary Hemorrhagic Telangiectasia (HHT, Osler-Weber-Rendu syndrome) was established as the most common hereditary cause of intrahepatic arteriovenous fistula. Hepatic vascular abnormalities (hepatic artery-portal vein shunts, hepatic artery-hepatic vein shunts, portal vein-hepatic vein shunts) are found on ultrasound or CT in about 40~70% of HHT patients, and of these, hepatic artery-portal vein shunts are the most clinically important form. Variants in the ENG (endoglin, HHT1) and ACVRL1 (ALK1, HHT2) genes were identified as the main causative genes of HHT in 1994 and 1996, respectively.
In Korea as well, cases of HHT-related hepatic vascular abnormalities have been reported, and isolated cases of congenital intrahepatic arteriovenous fistula are also rarely reported. Advances in Doppler ultrasound, CT, and MRI technology have made antemortem diagnosis possible, and advances in embolization techniques have improved treatment outcomes. Liver transplantation is performed when extensive HHT-related liver involvement does not respond to medical and interventional treatment, after which radical cure of HHT-related hepatic complications is possible. Recently, bevacizumab (an anti-VEGF antibody) has been used to control the systemic symptoms of HHT, and there are reports that it is also effective for hepatic vascular abnormalities.
ICD-10 Q26.6 is classified as congenital portal vein–hepatic artery fistula, but in clinical practice differentiation from the acquired form is important, and HHT-related hepatic vascular abnormalities are understood as a mixed form in which acquired vascular changes develop progressively on the basis of a congenital predisposition (gene variants). Upon registration under special copayment reduction V150, support for related medical expenses is available.
The causes of portal vein–hepatic artery fistula are divided into congenital and acquired. ICD-10 Q26.6 refers to the congenital form, which arises when an abnormal connection between an artery and the portal vein persists during the development of intrahepatic vessels in the embryonic period.
Congenital causes: during normal fetal development, intrahepatic arteries and veins are separated at the capillary level. When this separation is not completed in the embryonic period, or an abnormal arteriovenous connection forms and persists, congenital intrahepatic arteriovenous fistula develops. Such congenital fistulas are very rare and occur in isolation or as part of a congenital vascular dysplasia. Hereditary hemorrhagic telangiectasia (HHT) is a disease in which systemic vascular dysplasia arises from congenital gene variants (ENG, ACVRL1, SMAD4), and intrahepatic arteriovenous shunts (artery-portal vein, artery-vein, portal vein-vein) occur as the result of genetically determined abnormalities of vascular development.
Acquired causes: percutaneous liver biopsy is the most common acquired cause; as the needle passes through intrahepatic vascular structures, an abnormal connection may form between branches of the artery and the portal vein. Most small post-procedural arteriovenous fistulas close spontaneously, but some large fistulas cause clinically significant portal hypertension. Abdominal trauma (gunshot wounds, stab wounds, blunt injury) and liver procedures such as laparoscopic surgery, hepatectomy, percutaneous biliary intervention, and radiofrequency ablation (RFA) are also causes of acquired fistulas. In hepatocellular carcinoma and liver metastases, arteriovenous fistulas may form through intratumoral vascular invasion. Rupture of an aneurysm (hepatic artery aneurysm or intrahepatic vascular aneurysm) into the portal system is also a cause of acquired portal vein–hepatic artery fistula.
Celiac artery or hepatic artery lesions (aneurysm, atherosclerotic stenosis) themselves do not cause portal hypertension, but when arterial blood flows into the portal system after fistula formation, clinically important hemodynamic changes occur.
The most important element in the genetic basis of congenital portal vein–hepatic artery fistula is hereditary hemorrhagic telangiectasia (HHT, Osler-Weber-Rendu syndrome). HHT is an autosomal dominant genetic disease causing systemic vascular dysplasia, characterized by cutaneous and mucosal telangiectasias, epistaxis, gastrointestinal bleeding, and arteriovenous malformations of the lungs, liver, and brain.
The causative genes of HHT are mainly three. Variants in the ENG (endoglin, 12q13.13) gene cause HHT1; endoglin is a co-receptor of the TGF-β signaling pathway expressed in vascular endothelial cells and is involved in vascular development and stabilization. Heterozygous loss-of-function variants of ENG lead to reduced TGF-β signaling in vascular endothelial cells → abnormal vascular remodeling → formation of telangiectasias and arteriovenous malformations. Variants in the ACVRL1 (ALK1, 12q11-q14) gene cause HHT2; ALK1, an activin receptor-like kinase, plays an important role in vascular maturation and arteriovenous differentiation. ACVRL1 variants are more strongly associated with hepatic arteriovenous malformations than with pulmonary arteriovenous malformations. SMAD4 (18q21.2) variants cause a combined syndrome of HHT and juvenile polyposis syndrome (JPHT).
HHT shows typical autosomal dominant inheritance, and a heterozygous variant alone causes the disease. Penetrance increases with age, and clinical symptoms appear in most affected individuals by their 40s. Expressivity varies greatly even within the same family. The frequency of liver involvement differs by genotype, with hepatic arteriovenous malformations being more common and more severe with ALK1 (HHT2) variants.
Genetic causes of sporadic (non-HHT) congenital portal vein–hepatic artery fistula have not yet been established. Genes of the NOTCH and VEGF signaling pathways involved in hepatic vascular development are being studied as potential candidates, but no specific gene has been clinically confirmed. In patients with suspected HHT, diagnosis is made according to clinical criteria (Curaçao criteria: definite when 3 or more of epistaxis, mucosal telangiectasias, visceral arteriovenous malformations, and family history are met), and an ENG, ACVRL1, SMAD4 gene panel test is performed for molecular genetic confirmation.
Congenital portal vein–hepatic artery fistula (Q26.6) is a very rare vascular malformation, and the exact prevalence of isolated congenital occurrence has not been established. Only a few dozen cases have been reported in the literature, so epidemiological data are extremely limited. Acquired portal vein–hepatic artery fistula most commonly occurs after liver biopsy; in Doppler ultrasound follow-up studies after percutaneous liver biopsy, small arteriovenous fistulas are found in about 5~7%, but clinically significant ones are less than 1%.
The prevalence of HHT-related hepatic vascular abnormalities is relatively well known based on HHT patient cohorts. On Doppler ultrasound, intrahepatic vascular abnormalities are found in about 40~70% of HHT patients, and those causing clinically significant symptoms (heart failure, biliary ischemia, portal hypertension) are about 8~31%. Because the overall prevalence of HHT is estimated at about 1/5,000, the prevalence of symptomatic HHT-related hepatic vascular abnormalities is estimated at about 1/15,000~1/60,000. HHT occurs in all races worldwide, and liver involvement is more common in HHT2 (ALK1 variants).
As for sex distribution, HHT itself shows no sex difference, but there are reports that heart failure due to hepatic vascular abnormalities is more common in women. The age at which clinical symptoms appear is generally the 30s~60s, but it has also been reported in children. Epistaxis appears from a young age, whereas visceral arteriovenous malformations are often diagnosed in adulthood.
In acquired portal vein–hepatic artery fistula, liver biopsy is the most common cause; others include abdominal trauma and complications of liver procedures. Most arteriovenous fistulas after liver biopsy close spontaneously within 4~6 weeks, but when they persist, ultrasound follow-up and, if necessary, embolization are required. In Korea, liver biopsy is frequently performed for purposes such as evaluating liver lesions in hepatitis B and C patients and biopsy of liver cancer, so attention to surveillance for post-procedural vascular complications is needed.
The core pathophysiology of portal vein–hepatic artery fistula is that high-pressure arterial blood flows directly into the low-pressure portal system, causing portal hypertension and various resulting clinical complications.
Mechanism of portal hypertension: normally, the hepatic artery connects with the sinusoidal system at the capillary level within the liver, and the portal vein supplies oxygen-poor blood to the intralobular sinusoids. When a fistula forms between the hepatic artery and the portal vein, blood at arterial pressure (about 100 mmHg) flows directly into the portal system, whose normal pressure is 5~10 mmHg. This causes a sharp rise in portal pressure (portal hypertension), and complications such as splenomegaly, ascites, formation of esophageal and gastric varices, gastrointestinal bleeding, and hepatic encephalopathy develop.
High-output heart failure: with large arteriovenous shunts (especially extensive HHT-related liver involvement), blood flow through the shunt increases greatly, causing high-output cardiac failure with markedly increased cardiac output. The heart adapts to the increased preload, and cardiac output initially increases, but if this persists for a long time, the compensatory capacity of the heart is exhausted and it progresses to low-output heart failure. This is clinically important especially in extensive HHT-related hepatic arteriovenous malformations, and heart failure becomes a major indication for liver transplantation.
Biliary ischemia: when hepatic arterial flow is diverted through an arteriovenous shunt, blood flow to the peribiliary vascular plexus around the intrahepatic bile ducts decreases, and biliary ischemia may develop. This causes bile duct stricture, bile duct necrosis, and bile leakage, manifesting clinically as cholestatic hepatitis, biliary stricture, and recurrent cholangitis.
Changes in hepatic blood flow: when arterial blood flows into the portal system, portal blood flow to the hepatic parenchyma may reverse or decrease. This can lead to parenchymal ischemia, hepatocyte injury, and decreased liver function. Repeated ischemia-reperfusion injury and inflammation can promote hepatic fibrosis. Progression to cirrhosis has also been reported when the fistula is large and long-standing.
The clinical symptoms of portal vein–hepatic artery fistula vary depending on the size of the fistula, its location (intrahepatic or extrahepatic), the presence of HHT, and the shunt volume.
Childhood symptoms: children with a large congenital fistula may present with symptoms of heart failure (tachycardia, dyspnea, hepatomegaly), ascites, growth failure, and jaundice. A continuous bruit may be heard over the abdomen. In infants with heart failure or ascites of unknown cause, intrahepatic vascular abnormalities should be differentiated.
Adult symptoms: the main symptoms are ascites, esophageal and gastric variceal bleeding (hematemesis, melena), splenomegaly, and hepatic encephalopathy due to portal hypertension. Abdominal discomfort or right upper quadrant pain may accompany. With biliary ischemia due to diversion of hepatic arterial flow, recurrent cholangitis (fever, right upper quadrant pain, jaundice) appears. With large shunts, generalized edema, dyspnea, and fatigue due to high-output heart failure may appear.
Symptoms accompanying HHT: in HHT patients, systemic symptoms such as epistaxis (the most common symptom, from a young age), cutaneous and mucosal telangiectasias, gastrointestinal bleeding (a cause of chronic anemia), pulmonary arteriovenous malformations (dyspnea, cyanosis, stroke), and cerebral arteriovenous malformations (headache, seizures, cerebral hemorrhage) accompany. Liver involvement is found on ultrasound in a considerable number of HHT patients who have symptoms other than epistaxis.
Acquired (post-procedural, post-traumatic): when it occurs after liver biopsy, it mostly closes spontaneously within a few weeks and is asymptomatic. With persistent large fistulas, abdominal pain, abdominal bruit, and hematochezia or hematuria (to be differentiated from renal arteriovenous fistula) may appear. Post-traumatic fistulas sometimes present with complications of portal hypertension weeks to months after abdominal trauma.
Representative signs on physical examination are as follows.
Abdominal bruit: with intrahepatic or extrahepatic arteriovenous fistulas, a systolic or continuous bruit is heard with a stethoscope over the abdomen (especially the right upper quadrant and epigastrium). This is an important clue to the diagnosis of arteriovenous fistula. It is not heard in all patients and may be inaudible when the fistula is small or deep.
Signs of portal hypertension: splenomegaly (spleen palpable or enlarged on percussion), ascites (shifting dullness, fluid wave), dilated upper abdominal veins (caput medusae is rare), lower extremity edema, and inguinal hernia may accompany. Esophageal and gastric varices are found on upper gastrointestinal endoscopy.
Hepatomegaly: the liver is palpable or enlarged on percussion, and a thrill may be felt over the fistula site.
Signs of heart failure: tachycardia, jugular venous distension, peripheral edema, gallop rhythm, and pulmonary crackles are observed in high-output heart failure. Signs of both left- and right-sided heart failure may appear, accompanied by bilateral pulmonary crackles and pleural effusion.
Signs of HHT: mucosal telangiectasias of the lips, tongue, and fingertips, telangiectasias of the nasal septum, nail clubbing (with coexisting pulmonary arteriovenous malformations), and focal vascular bruits on lung auscultation are observed.
Laboratory findings: elevated serum bilirubin, elevated alkaline phosphatase (with biliary ischemia), thrombocytopenia (with splenomegaly and hypersplenism), decreased serum albumin, prolonged prothrombin time (with advanced decline in liver function), and anemia (with chronic gastrointestinal bleeding) appear.
Screening of the general population for portal vein–hepatic artery fistula is not performed. Screening targeting HHT patients and patients after liver procedures is clinically important.
Screening of HHT patients: in patients with confirmed HHT, Doppler abdominal ultrasound is performed to screen for hepatic vascular abnormalities. When ultrasound shows abnormal findings (intrahepatic arteriovenous shunts, hepatomegaly, abnormal vascular patterns), they are confirmed with CT or MR angiography. When HHT patients show evidence of high-output heart failure or biliary complications, detailed evaluation for treatment decisions is needed. Given the autosomal dominant inheritance of HHT, family members of HHT patients are advised to receive genetic counseling and clinical diagnostic evaluation.
Screening after liver procedures: Most arteriovenous fistulas occurring after percutaneous liver biopsy close spontaneously, so follow-up ultrasound is not performed in all patients. If symptoms of bleeding or hemodynamic instability such as hypotension, abdominal pain, or bloody stool occur after the procedure, immediate abdominal Doppler ultrasound or CT is performed. If a persistent arteriovenous fistula is suspected (symptoms persisting 4–6 weeks after the procedure), follow-up ultrasound is used to confirm the vascular abnormality.
Unexplained portal hypertension or heart failure: In patients with unexplained portal hypertension, ascites, gastrointestinal bleeding, or high-output heart failure, intrahepatic vascular abnormalities (including arteriovenous fistula) are included in the differential diagnosis and abdominal Doppler ultrasound is performed.
Diagnosis of arterioportal fistula includes confirmation of vascular anatomy and assessment of hemodynamic effects.
Abdominal Doppler ultrasound: As the first-line noninvasive test, it assesses abnormal intrahepatic vascular connections, portal flow direction and velocity (retrograde portal flow is an important finding of a large fistula), splenomegaly, and ascites. High-velocity pulsatile flow at the arteriovenous fistula site (mosaic color pattern) on color Doppler is characteristic.
CT/MR angiography: Precisely identifies the location and size of the fistula, the feeding artery, and the draining portal branch, and assesses hepatic parenchymal damage (infarction, fibrosis), biliary abnormalities, splenomegaly, and ascites. Dynamic contrast-enhanced CT (arterial, portal, delayed phase) visualizes early enhancement of the arteriovenous fistula, retrograde opacification of the portal vein, and biliary injury. MRI can be used repeatedly without radiation and is advantageous for assessing hepatic parenchymal damage and biliary abnormalities.
Angiography: Selective celiac angiography is the most sensitive for confirming the precise anatomy of the fistula and the feeding artery, and embolization treatment can be performed at the same time. Transjugular measurement of the hepatic venous pressure gradient (HVPG) for portal pressure measurement can also be performed.
Liver function tests and blood tests: Include bilirubin, alkaline phosphatase, gamma-GT, albumin, prothrombin time, platelets, hemoglobin, anemia indices, and serum ammonia (assessment of hepatic encephalopathy).
Cardiac evaluation: To evaluate high-output heart failure, echocardiography (measurement of ejection fraction, cardiac output, and pulmonary artery pressure), electrocardiography, and brain natriuretic peptide (BNP/NT-proBNP) are tested.
Treatment of arterioportal fistula is determined by the size of the fistula, the severity of clinical symptoms, and whether HHT is present.
Transcatheter arterial embolization (TAE): Currently the method chosen as first-line treatment. After the feeding artery is identified by selective celiac or hepatic angiography, the fistula is occluded using coils, a vascular plug (Amplatzer vascular plug), or liquid embolic agents (NBCA, etc.). The success rate is about 70–90%, and repeat procedures are sometimes needed. Because there is a risk of hepatic or biliary ischemia after the procedure, careful procedural planning is required.
Surgical treatment: Surgical ligation or resection is performed when a percutaneous approach is difficult or has failed, or for fistulas in complex anatomical locations. Surgery is sometimes needed in children with large congenital fistulas.
Liver transplantation: Liver transplantation is performed when refractory high-output heart failure, biliary ischemia, or severe portal hypertension due to extensive HHT-related hepatic arteriovenous malformations does not respond to embolization. Liver transplantation cures the liver-related complications of HHT, but systemic HHT (pulmonary, cerebral, and gastrointestinal arteriovenous malformations) persists.
Systemic treatment of HHT: The efficacy of bevacizumab (an anti-VEGF monoclonal antibody) for epistaxis, gastrointestinal bleeding, and pulmonary arteriovenous malformations in HHT is being studied, and some efficacy has also been reported for hepatic vascular abnormalities and heart failure. Angiogenesis inhibitors such as thalidomide and pazopanib are also under study.
Medical supportive treatment: For portal hypertension, diuretics, (nonselective) beta-blockers, and endoscopic variceal ligation are used. For heart failure, standard heart failure treatment such as diuretics and angiotensin-converting enzyme inhibitors is given concurrently. Antibiotic treatment is required for biliary infection.
The prognosis of arterioportal fistula varies according to the type and size of the fistula, the presence and severity of clinical complications, and the timing of treatment.
Small acquired fistulas: Most small fistulas occurring after liver biopsy close spontaneously within 4–6 weeks, with good clinical outcomes. Most small-to-medium congenital or acquired fistulas treated by embolization are also successfully occluded, and portal hypertension improves.
HHT-related liver involvement: Asymptomatic or mild hepatic vascular abnormalities (found on ultrasound) can remain stable for a long time with conservative management. When high-output heart failure develops, the prognosis is poor, and embolization or liver transplantation is required. Successful liver transplantation can resolve heart failure and heal biliary ischemia, but systemic HHT symptoms persist. Untreated high-output heart failure carries a high risk of death.
Biliary ischemia: When biliary ischemia has progressed, complications such as bile duct stricture, cholangitis, and liver abscess recur, and the prognosis is poor. Liver transplantation is the only curative treatment for biliary ischemia.
Long-term follow-up: Regular abdominal Doppler ultrasound follow-up is needed after embolization or surgery to check for recurrence. In HHT patients, ongoing evaluation and management of systemic vascular abnormalities (lung, brain, gastrointestinal tract) must be carried out as well.
Primary prevention of congenital arterioportal fistula is difficult. For HHT, genetic counseling and prenatal diagnosis are available as prevention, but because the clinical spectrum of HHT itself is very diverse and many cases are mild, preimplantation genetic testing (PGT) is performed only selectively.
Prevention of complications through management of HHT patients (secondary prevention): Patients with confirmed HHT are checked for hepatic vascular abnormalities with regular Doppler ultrasound. When a clinically significant shunt is identified, embolization or multidisciplinary evaluation is performed early to prevent progression to heart failure, biliary ischemia, and portal hypertension. In HHT patients, percutaneous liver procedures (biopsy, etc.) are avoided when not essential, because of the risk of worsening vascular abnormalities or bleeding.
Precautions after liver procedures (tertiary prevention): If hemodynamic instability, abdominal pain, bloody stool, etc. occur after percutaneous liver biopsy, abdominal Doppler ultrasound is performed immediately to check for arteriovenous fistula or bleeding. Large fistulas occurring after a procedure are observed in expectation of spontaneous closure, but embolization is performed if symptoms of portal hypertension develop.